Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. (PubMed, BioDrugs) - Nov 17, 2025 - P3 | "Xeligekimab demonstrated significant efficacy in improving the signs and symptoms of active r-axSpA in Chinese patients at week 16, with sustained effects observed through week 48 and no new safety signals identified."
Clinical • Journal • P3 data • Ankylosing Spondylitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A
|
|
Baijie Xu; Chunyan Zhang; Dong Xu; Dongmei Zhou; Fenghong Yuan; Guohua Yuan; Hongsheng Sun; Hua Wei; Hua Zhang; Jian Xu; Jiankang Hu; Jie Hao; Jieruo Gu; Jing Yang; Jingchun Jin; Ju Liu; Li Qin; Li Sun; Lie Dai; Lingli Dong; Lingyun Sun; Long Qian; Min Yang; Ning Kong; Ning Zhang; Qiang Shu; Shangzhu Zhang; Shengyun Liu; Shujie Li; Tao Jiang; Tianwang Li; Wei Gou; Wei Wang; Wenqiang Fan; Xiaofeng Zeng; Xiaomei Li; Xiaoxia Wang; Xiaoyan Cai; Xiaoyun Fan; Yi Zhao; Zhanyun Da; Zhenyu Jiang
|